RxDoctor Payments Data

David Sumerford

Psychiatric/Mental Health · Tupelo, MSNPI 1508193459

Payments from drug & device makers

$2,847in general payments, 2019–2025

Across 193 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$957
  • AbbVie$604
  • Johnson & Johnson$337
  • Otsuka America Pharmaceutical, Inc.$234
  • Takeda Pharmaceuticals U.S.A., Inc.$200
  • Alkermes, Inc.$115
  • plus $400 from 11 others

What the payments were for

  • Food & beverage$2,80098%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,847 in reported general payments places this provider in the 80th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$104,444
Medicare patients
256
Services billed
1,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,452
VraylarCariprazine Hcl41$58,579
SpravatoEsketamine Hcl47$54,491
CaplytaLumateperone Tosylate27$47,462
RexultiBrexpiprazole26$40,957
TrintellixVortioxetine Hydrobromide45$21,453
Venlafaxine Hcl ErVenlafaxine Hcl98$4,732
BelsomraSuvorexant11$4,645
Aripiprazole103$3,634
Vilazodone Hcl19$2,193
Hydroxyzine Hcl58$1,599
Divalproex Sodium ErDivalproex Sodium84$1,516
Quetiapine Fumarate141$1,469
Duloxetine Hcl122$1,186
Hydroxyzine Pamoate91$1,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$604$58,57941 claims
Johnson & JohnsonSpravato$337$54,49147 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$957$47,46227 claims
Otsuka America Pharmaceutical, Inc.Rexulti$234$40,95726 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$200$21,45345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →